Måndag 19 Oktober | 09:49:54 Europe / Stockholm
Est. tid*
2027-02-22 08:30 Bokslutskommuniké 2026
2026-08-28 - Kvartalsrapport 2026-Q2
2026-05-29 - X-dag ordinarie utdelning HEART 0.00 SEK
2026-05-28 - Årsstämma
2026-02-19 - Bokslutskommuniké 2025
2025-12-16 - Extra Bolagsstämma 2025
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-12 - X-dag ordinarie utdelning HEART 0.00 SEK
2025-06-11 - Årsstämma
2025-02-26 - Bokslutskommuniké 2024
2024-11-21 - Split HEART 100:1
2024-11-14 - 15-10 2024-Q3
2024-11-05 - Extra Bolagsstämma 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-06-10 - X-dag ordinarie utdelning HEART 0.00 SEK
2024-06-07 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-24 - Extra Bolagsstämma 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-06-16 - Årsstämma
2023-06-15 - X-dag ordinarie utdelning HEART 0.00 SEK
2023-06-14 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-19 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning HEART 0.00 SEK
2022-06-14 - Årsstämma
2022-05-20 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-08-05 - Extra Bolagsstämma 2021
2021-05-20 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning HEART 0.00 SEK
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-08-04 - Extra Bolagsstämma 2020
2020-05-20 - Kvartalsrapport 2020-Q1
2020-05-19 - X-dag ordinarie utdelning HEART 0.00 SEK
2020-05-18 - Årsstämma
2020-02-27 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-23 - Kvartalsrapport 2019-Q1
2019-03-27 - X-dag ordinarie utdelning HEART 0.00 SEK
2019-03-26 - Årsstämma
2019-02-27 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-05-11 - X-dag ordinarie utdelning HEART 0.00 SEK
2018-02-22 - Bokslutskommuniké 2017
2017-11-27 - Extra Bolagsstämma 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-31 - Kvartalsrapport 2017-Q1
2017-05-11 - X-dag ordinarie utdelning HEART 0.00 SEK
2017-05-10 - Årsstämma
2017-02-23 - Bokslutskommuniké 2016
2016-11-24 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-11 - Kvartalsrapport 2016-Q1
2016-05-10 - Årsstämma
2016-04-20 - X-dag ordinarie utdelning HEART 0.00 SEK
2016-02-18 - Bokslutskommuniké 2015
2015-11-12 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-05-26 - Kvartalsrapport 2015-Q1
2015-05-21 - X-dag ordinarie utdelning HEART 0.00 SEK
2015-05-20 - Årsstämma
2015-02-18 - Bokslutskommuniké 2014
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandinavian Real Heart är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling inom observationer av hjärtats fysiologi. Utvecklingen av bolagets produkt, ett komplett artificiellt hjärta, sker i samarbete med hjärtkirurger, forskare och ingenjörer. Fokus ligger på att utveckla patenterade lösningar som kan imitera det naturliga mänskliga hjärtats blodcirkulation, med mål att användas av patienter som diagnostiserats med hjärtsvikt. Bolaget grundades år 2007.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Peer-Reviewed Study Demonstrates Preserved Platelet Function in Realheart® TAH

2026-10-19 08:30:00

Västerås, Sweden, October 19, 2026 - Scandinavian Real Heart AB (publ) today announces that a new peer-reviewed study published in the scientific journal Platelets demonstrates preserved platelet function following circulation in the Realheart® Total Artificial Heart (TAH). The findings provide further evidence supporting the device's hemocompatibility profile and complement previously published results showing low blood trauma in Realheart® TAH.

Platelets play a critical role in blood clotting and are involved in both bleeding and thrombotic complications associated with mechanical circulatory support devices. While hemolysis and other blood compatibility measures are commonly evaluated, platelet function represents another important aspect of device safety and performance.

The study assessed multiple aspects of platelet function after circulation through the Realheart® TAH under clinically relevant laboratory conditions. Using several complementary analytical methods, the researchers evaluated platelet integrity, responsiveness, activation status and clotting-related functionality. The results showed that platelets retained their functionality and responsiveness after circulation through the Realheart® TAH. Importantly, the study found no evidence of impaired platelet functionality or clotting-related responses attributable to the device.

“Artificial heart systems must achieve a high degree of blood compatibility to support long-term clinical use. This study demonstrates preserved platelet function after circulation through the Realheart® TAH and complements our previously published hemolysis findings. Together, these results strengthen the scientific foundation supporting the continued development of our technology,” says Ina Laura Perkins, CEO of Scandinavian Real Heart.

The study concludes that platelet function represents an important and distinct aspect of hemocompatibility that should be evaluated alongside other blood compatibility parameters when assessing artificial heart technologies. The publication expands Scandinavian Real Heart’s growing body of scientific evidence supporting the development of the Realheart® TAH, a total artificial heart designed to mimic the physiology of the natural human heart through its unique pulsatile, four-chamber design. Together with previously published studies demonstrating favorable hemocompatibility characteristics, the findings contribute to a broader understanding of the device’s interaction with blood components, and important consideration in the development of mechanical circulatory support systems.

The article, entitled “Functionality of platelets after in vitro testing of pulsatile total artificial hearts”, was authored by researchers from Karolinska Institutet and Scandinavian Real Heart and has been published in the peer-reviewed journal Platelets. The publication is available at: https://doi.org/10.1080/09537104.2026.2741743